Thomas Tillett - President & CEO

He is Executive Director of Sustained Acts, a non-profit focusing on sustainable projects in Africa as well as supporting a 120 child orphanage in Kenya. Mr. Tillett is also CEO of TillettConsulting, LLC a life science consulting firm focusing on the cell and gene therapy markets and mentoring of startup companies. He has served as Chairman of the BioIndustrial Liaison Committee for the American Society of Gene and Cell Therapy, a position that provides him unique insights into the latest developments in new immunotherapeutics. Mr. Tillett was founder, President and CEO of RHeoGene LLC. He started the company in 1999 as a joint venture between Rohm and Haas Company and Argonex (Charlottesville VA). In 2003, he led the highly innovative and unique effort to donate the intellectual property and material assets of RHeoGene LLC to the University of Pittsburgh Medical Center (UPMC), which became RheoGene, Inc. As RheoGene CEO, he established an innovative clinical development program with the RheoSwitch® Therapeutic System (RTS) that has led to the first human clinical trial of a small molecule-induced gene regulation system. This represented a major advance in gene therapy that should lead to significant improvements in safer and more controllable forms of gene therapy. In 2007, he successfully completed the merger of RheoGene Inc. with Intrexon Corporation. Mr. Tillett was also a co-founder of Immunotope, Inc., a cancer immunotherapy company, and a former member of the Board of Advisors of the McGowan Institute for Regenerative Medicine, a research institute of the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC) Health System in Pittsburgh, Pennsylvania.

--Close Window--


Lorraine H. Keller, Ph.D. - CSO

Travis Meredith, DVM, MBA, Diplomate ACT – Founding Partner

Management Team:

Board of Directors:

Clinical Advisory Board:

Corporate Counsel:

  • LinkedIn Classic
  • Facebook Classic
  • Twitter Social Icon

​Follow us at @mbftherapeutics

© 2020 MBF Therapeutics.   Advanced Immunotherapeutics for Life Sciences.  All rights reserved.